MarketCap
Facebook
X
TelegramOxford Immunotec Global PLC Long-Term Debt | OXFD
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Oxford Immunotec Global PLC
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | 32 K | 106 K | 29.9 M | 29.6 M | 386 K | 454 K | 563 K | 143 K | 140 K |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 29.9 M | 32 K | 6.81 M |
Long-Term Debt of other stocks in the Diagnostics research industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 257.93 | 1.18 % | $ 28.6 B |  USA |
 |
Danaher Corporation
DHR
|
18.4 B | $ 230.45 | 1.76 % | $ 164 B | USA |
 |
IDEXX Laboratories
IDXX
|
375 M | $ 676.3 | 0.83 % | $ 54.4 B | USA |
 |
Illumina
ILMN
|
486 M | $ 213.05 | 2.43 % | $ 33 B | USA |
 |
Lantheus Holdings
LNTH
|
569 M | $ 100.61 | -0.09 % | $ 6.79 B | USA |
 |
Accelerate Diagnostics
AXDX
|
30 K | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
114 M | $ 653.24 | 2.88 % | $ 18.8 B | USA |
 |
Mettler-Toledo International
MTD
|
2.09 B | $ 1 722.36 | 2.64 % | $ 35.5 B |  Schweiz |
 |
Natera
NTRA
|
118 M | $ 319.38 | -12.2 % | $ 43.7 B | USA |
 |
Charles River Laboratories International
CRL
|
2.14 B | $ 338.13 | 8.07 % | $ 16.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
5.7 B | $ 30.33 | -0.57 % | $ 28.8 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
1.65 B | $ 50.36 | -0.98 % | $ 10.9 B | Niderland |
 |
RadNet
RDNT
|
1.06 B | $ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
35.6 M | $ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
6.6 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
1.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
65.8 M | $ 2.17 | -10.91 % | $ 143 M | USA |
 |
Thermo Fisher Scientific
TMO
|
39.2 B | $ 694.85 | 2.62 % | $ 262 B | USA |
 |
Akumin
AKU
|
1.25 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
82.7 M | $ 6.07 | 2.97 % | $ 2.18 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
4.8 M | $ 11.12 | 4.81 % | $ 378 M |  Israel |
 |
VolitionRx Limited
VNRX
|
5.82 M | $ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
947 M | $ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
22.3 M | $ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
1.5 B | $ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
5.08 B | $ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
13.9 B | $ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
233 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
76.7 K | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
38 K | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
29.6 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
3.78 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
2.61 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
1.24 M | - | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
307 K | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
546 K | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
41 K | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
53 K | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
25 M | - | - | $ 1.49 B | USA |
 |
Celcuity
CELC
|
138 M | $ 66.73 | 3.9 % | $ 3.12 B | USA |
 |
DexCom
DXCM
|
53.8 M | $ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
3.05 B | $ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Castle Biosciences
CSTL
|
9.64 M | $ 32.49 | -4.99 % | $ 942 M | USA |
 |
Anixa Biosciences
ANIX
|
163 K | $ 3.16 | 4.29 % | $ 103 K | USA |
|
Biodesix
BDSX
|
50 M | $ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
3.48 M | $ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
279 M | $ 10.61 | -0.66 % | $ 707 M | USA |
 |
Fulgent Genetics
FLGT
|
360 K | $ 23.68 | 26.9 % | $ 729 M | USA |
 |
CareDx, Inc
CDNA
|
19.7 M | $ 78.47 | 2.8 % | $ 4.18 B | USA |